在Xigris之后，研究人员寻找对抗败血症的新靶点。 - Suppr

After Xigris, researchers look to new targets to combat sepsis.

作者信息

Williams Sarah C P

出版信息

Nat Med. 2012 Jul 6;18(7):1001. doi: 10.1038/nm0712-1001.

DOI:10.1038/nm0712-1001

PMID:22772543

Abstract

摘要

相似文献

After Xigris, researchers look to new targets to combat sepsis.

Nat Med. 2012 Jul 6;18(7):1001. doi: 10.1038/nm0712-1001.

Drotrecogin alfa (activated) for severe sepsis.

Drug Ther Bull. 2006 Jan;44(1):5-8. doi: 10.1136/dtb.2006.4415.

[A word of warning about economic evaluations].

Gac Sanit. 2004 Nov-Dec;18(6):486; author reply 487-8. doi: 10.1016/s0213-9111(04)72038-5.

Appraisal of treatment for severe sepsis in intensive care units.

Ann R Coll Surg Engl. 2005 Jul;87(4):283-4.

Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.

Am J Health Syst Pharm. 2006 Aug 1;63(15):1453-60. doi: 10.2146/ajhp050262.

[Medical-economic evaluation of severe sepsis].

Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:28-30.

Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).

Am J Crit Care. 2003 Mar;12(2):94-7.

Cost-effectiveness of drotrecogin alfa (activated).

Crit Care Med. 2003 Sep;31(9):2414-5; author reply 2415. doi: 10.1097/01.CCM.0000087000.98485.5D.

Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

Pharmacoeconomics. 2004;22(7):445-76. doi: 10.2165/00019053-200422070-00004.

Activated protein C (Xigris): a drug in trouble.

Acta Anaesthesiol Scand. 2007 Feb;51(2):261-2. doi: 10.1111/j.1399-6576.2006.01215.x.

引用本文的文献

Thromboinflammation in Sepsis and Heparin: A Review of Literature and Pathophysiology.

In Vivo. 2022 Nov-Dec;36(6):2542-2557. doi: 10.21873/invivo.12991.

A Thrombomodulin Promoter Gene Polymorphism, rs2239562, Influences Both Susceptibility to and Outcome of Sepsis.

Front Med (Lausanne). 2022 Jan 10;8:762198. doi: 10.3389/fmed.2021.762198. eCollection 2021.

Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia.

Immunity. 2022 Feb 8;55(2):224-236.e5. doi: 10.1016/j.immuni.2021.12.002. Epub 2022 Jan 6.

Sirtuin 2 Dysregulates Autophagy in High-Fat-Exposed Immune-Tolerant Macrophages.

Cells. 2021 Mar 26;10(4):731. doi: 10.3390/cells10040731.

Mucosal-associated invariant T (MAIT) cells mediate protective host responses in sepsis.

Elife. 2020 Nov 9;9:e55615. doi: 10.7554/eLife.55615.

Epigenetic and metabolic programming of innate immunity in sepsis.

Innate Immun. 2019 Jul;25(5):267-279. doi: 10.1177/1753425919842320. Epub 2019 Apr 18.

Sirtuins and Immuno-Metabolism of Sepsis.

Int J Mol Sci. 2018 Sep 13;19(9):2738. doi: 10.3390/ijms19092738.

Potential Immunotherapeutics for Immunosuppression in Sepsis.

Biomol Ther (Seoul). 2017 Nov 1;25(6):569-577. doi: 10.4062/biomolther.2017.193.

Sirtuin 2 Regulates Microvascular Inflammation during Sepsis.

J Immunol Res. 2017;2017:2648946. doi: 10.1155/2017/2648946. Epub 2017 Apr 19.

Proteome analysis of hemofilter adsorbates to identify novel substances of sepsis: a pilot study.

J Artif Organs. 2017 Jun;20(2):132-137. doi: 10.1007/s10047-016-0936-3. Epub 2016 Nov 17.

本文引用的文献

A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.

Crit Care. 2012 Feb 17;16(1):R31. doi: 10.1186/cc11203.

Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.

JAMA. 2009 Jun 17;301(23):2445-52. doi: 10.1001/jama.2009.856.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

After Xigris, researchers look to new targets to combat sepsis.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献